Pedro Nofal
Overview
Explore the profile of Pedro Nofal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
60
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silva B, Heriz A, Ayerbe J, Lazaro L, Casas M, Lopez P, et al.
Neurol Sci
. 2024 Sep;
45(12):5841-5848.
PMID: 39259243
Introduction: Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been...
2.
Piedrabuena M, Correale J, Fiol M, Marrodan M, Rojas J, Alonso M, et al.
J Neurol Sci
. 2024 May;
461:123052.
PMID: 38797140
Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is...
3.
Carnero Contentti E, Lopez P, Pappolla A, Alonso R, Silva B, Deri N, et al.
Neurol Sci
. 2023 Dec;
45(2):379-389.
PMID: 38159147
Methods: Non-interventional, retrospective cohort study that collected information directly from RelevarEM. Adult PwMS who had been treated for at least 6 months with a HET (ocrelizumab, natalizumab, alemtuzumab, cladribine) who...
4.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, et al.
Mult Scler Relat Disord
. 2023 Aug;
79:104935.
PMID: 37634468
Background: Disease-modifying therapies (DMTs) in multiple sclerosis (MS) can be classified according to the efficacy in which they prevent inflammatory activity. To date, there are limited data regarding the use...
5.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, et al.
Mult Scler J Exp Transl Clin
. 2023 Feb;
9(1):20552173231154712.
PMID: 36846108
Background: We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and...
6.
Rojas J, Luetic G, Vrech C, Pappolla A, Patrucco L, Cristiano E, et al.
Mult Scler Relat Disord
. 2022 Sep;
68:104104.
PMID: 36057175
Methods: cohort study conducted between May 2021 and December 2021. The primary outcome was the appearance of infection during the follow-up time (at least three months after complete vaccination (second...
7.
Luetic G, Menichini M, Vrech C, Pappolla A, Patrucco L, Cristiano E, et al.
Mult Scler Relat Disord
. 2022 Feb;
58:103401.
PMID: 35216784
Background: In multiple sclerosis demographics there is a well-known female prevalence and male patients have been less specifically evaluated in clinical studies, though some clinical differences have been reported between...
8.
Rojas J, Pappolla A, Blaya P, Marrodan M, Ysrraelit M, Luetic G, et al.
J Neurol
. 2021 Sep;
269(4):2073-2079.
PMID: 34491406
Introduction: We aimed to analyze the accumulative risk of MRI and OB factors for evolution from RIS to MS in subjects included in the Argentinean MS registry (NCT03375177). Methods: RIS...
9.
Bonardo P, Leon Cejas L, Mazziotti J, Zinnerman A, Fernandez Pardal M, Martinez A, et al.
Medicina (B Aires)
. 2021 Aug;
81(4):588-596.
PMID: 34453801
Up to 15% of all strokes affect young patients and the incidence of ischemic stroke in this population is rising. Nevertheless, there is limited information of cerebrovascular events in this...
10.
Kohler M, Kohler E, Vrech C, Pappolla A, Miguez J, Patrucco L, et al.
J Clin Neurosci
. 2021 Jun;
89:360-364.
PMID: 34088579
Methods: The eligible study population and cohort selection included adult-onset patients (≥18 years) with definite MS. AMS were defined as those reaching confirmed EDSS ≥ 6 within 5 years from...